OS Therapies, EVERSANA Commercialize OST-HER2
June 10, 2025
OS Therapies Inc., a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, has selected EVERSANA, a leading provider of global commercial services to the life